From: Plasma contact factors as novel biomarkers for diagnosing Alzheimer’s disease
Characteristics | Normal (n = 50) vs. Prodromal AD (n = 23) groups | Normal (n = 50) vs. AD dementia (n = 28) groups | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Cut-off | Sen (%) | Spe (%) | AUC | p value | Cut-off | Sen (%) | Spe (%) | AUC | p value | |
Plasma factors | ||||||||||
FXIIa activity, U/ml | > 26.3 | 73.9 | 74.0 | 0.783 | < 0.001 | > 27.2 | 78.6 | 78.0 | 0.906 | < 0.001 |
FXIa activity, U/ml | > 1.13 | 52.2 | 52.0 | 0.566 | 0.367 | > 1.17 | 57.1 | 58.0 | 0.659 | 0.020 |
FXa activity, U/ml | > 0.76 | 56.5 | 54.0 | 0.573 | 0.316 | > 0.82 | 71.4 | 70.0 | 0.779 | < 0.001 |
Kallikrein activity, U/ml | > 1.21 | 56.5 | 56.0 | 0.609 | 0.138 | > 1.29 | 64.3 | 64.0 | 0.772 | < 0.001 |
CSF biomarkers | ||||||||||
Aβ1–42 levels, pg/ml | < 832.4 | 87.0 | 88.0 | 0.962 | < 0.001 | < 721.7 | 89.3 | 98.0 | 0.979 | < 0.001 |
t-Tau levels, pg/ml | > 252.6 | 65.2 | 66.0 | 0.701 | 0.006 | > 315.3 | 85.7 | 86.0 | 0.954 | < 0.001 |
p-Tau181 levels, pg/ml | > 46.1 | 65.2 | 64.0 | 0.690 | 0.009 | > 46.1 | 78.6 | 78.0 | 0.870 | < 0.001 |
BK levels, pg/ml | > 46.1 | 54.5 | 56.5 | 0.656 | 0.073 | > 52.8 | 74.1 | 73.9 | 0.783 | 0.001 |
Ratios | ||||||||||
Aβ1–42 / FXIIa | < 33.8 | 87.0 | 86.0 | 0.965 | < 0.001 | < 27.4 | 100.0 | 100.0 | 1.000 | < 0.001 |
Aβ1–42 / FXIa | < 742.5 | 82.6 | 82.0 | 0.930 | < 0.001 | < 635.4 | 96.4 | 96.0 | 0.993 | < 0.001 |
Aβ1–42 / FXa | < 1,091 | 82.6 | 82.0 | 0.933 | < 0.001 | < 941.8 | 96.4 | 96.0 | 0.994 | < 0.001 |
Aβ1–42 / Kallikrein | < 680.9 | 87.0 | 86.0 | 0.943 | < 0.001 | < 584.8 | 96.4 | 96.0 | 0.994 | < 0.001 |